Want to see JP:4502 full AI Analyst Report?
4502 Stock Chart & Stats
¥5648.00
¥121.00(2.14%)
At close: 4:00 PM EDT
¥5648.00
¥121.00(2.14%)
Day’s Range― - ―
52-Week Range¥4,102.00 - ¥6,033.00
Previous CloseN/A
Volume4.65M
Average Volume (3M)4.35M
Market Cap
¥9.30T
Enterprise Value¥12.75M
Total Cash (Recent Filing)¥527.58B
Total Debt (Recent Filing)¥4.94T
Price to Earnings (P/E)50.5
Beta0.31
Next Earnings
Oct 29, 2026EPS Estimate
45.7Next Dividend Ex-DateN/A
Dividend Yield3.47%
Share Statistics
EPS (TTM)114.22
Shares Outstanding1,602,106,800
10 Day Avg. Volume4,483,280
30 Day Avg. Volume4,345,693
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)1.15
Price to Sales (P/S)1.98
P/FCF Ratio11.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥6,700.00Price Target Upside18.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)121.2
Revenue Forecast (FY)¥4.68T
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSubstantial operating and free cash flow supports research investment, debt management, shareholder distributions, and product launches. This financial capacity gives Takeda flexibility to fund growth while absorbing development and commercialization costs.
Pipeline And Launch MomentumMultiple late-stage assets and launches can diversify growth beyond mature products. ORZEYFUL provides an approved new commercial opportunity, while rusfertide and zasocitinib could add meaningful future revenue if regulatory and launch execution remain successful.
Improving LeverageImproving leverage and a larger equity base strengthen financial resilience for a global pharmaceutical company. A more manageable debt burden should preserve capacity for R&D, business development, and launch investment through changing operating conditions.
Bears Say
Mature Portfolio ErosionLoss of exclusivity and generic competition create persistent pressure on established-product revenue and margins. Takeda must replace declining products with new launches and pipeline successes, increasing dependence on execution and regulatory outcomes.
Thin And Volatile Net ProfitabilityLow and variable bottom-line profitability limits the conversion of strong gross and operating economics into shareholder returns. Sensitivity to costs, non-operating items, and other below-the-line pressures may constrain earnings durability.
Recent Constant-Currency SoftnessUnderlying performance is weaker than reported growth suggests because currency translation provided material support. Investment behind launches, mature-product headwinds, and a lower core EPS base indicate that organic growth and earnings conversion remain pressured.
4502 FAQ
What was Takeda Pharmaceutical Co Ltd’s price range in the past 12 months?
Takeda Pharmaceutical Co Ltd lowest stock price was ¥4102.00 and its highest was ¥6033.00 in the past 12 months.
What is Takeda Pharmaceutical Co Ltd’s market cap?
Takeda Pharmaceutical Co Ltd’s market cap is ¥9.30T.
When is Takeda Pharmaceutical Co Ltd’s upcoming earnings report date?
Takeda Pharmaceutical Co Ltd’s upcoming earnings report date is Oct 29, 2026 which is in 67 days.
How were Takeda Pharmaceutical Co Ltd’s earnings last quarter?
Takeda Pharmaceutical Co Ltd released its earnings results on Jul 30, 2026. The company reported ¥71.65 earnings per share for the quarter, beating the consensus estimate of ¥54.38 by ¥17.27.
Is Takeda Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Takeda Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Takeda Pharmaceutical Co Ltd pay dividends?
Takeda Pharmaceutical Co Ltd pays a Semiannually dividend of ¥102 which represents an annual dividend yield of 3.47%. See more information on Takeda Pharmaceutical Co Ltd dividends here
What is Takeda Pharmaceutical Co Ltd’s EPS estimate?
Takeda Pharmaceutical Co Ltd’s EPS estimate is 45.7.
How many shares outstanding does Takeda Pharmaceutical Co Ltd have?
Takeda Pharmaceutical Co Ltd has 1,602,106,800 shares outstanding.
What happened to Takeda Pharmaceutical Co Ltd’s price movement after its last earnings report?
Takeda Pharmaceutical Co Ltd reported an EPS of ¥71.65 in its last earnings report, beating expectations of ¥54.38. Following the earnings report the stock price went down -2.206%.
Which hedge fund is a major shareholder of Takeda Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4502
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
4502 Company Deck
4502 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of modest near-term CER declines and cash-flow timing effects against substantial positive developments: strong FX-driven reported results, confirmation of transformation-led funding for launches, multiple imminent regulatory and commercial milestones (ORZEYFUL approval in China; rusfertide priority review; superior zasocitinib data), and a robust late-stage pipeline with several programs moving to pivotal stages. While Q1 contained some one-time impacts, transitional investment effects and product-specific headwinds, the combination of pipeline momentum, launch readiness and a maintained full-year financial outlook suggests the company is positioned to convert R&D progress into revenue growth later in the year.View all JP:4502 earnings summaries4502 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
¥6,700.00
▲(18.63% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
―
Shionogi & Co
―
Nippon Shinyaku Co., Ltd.
―










